Verastem shares jump 20% after positive cancer drug trial update
Verastem Oncology shares rose 20% Thursday, their best day since November 2025, after a positive update on experimental drug VS-7375 in second-line metastatic pancreatic ductal adenocarcinoma. Analysts also lifted price targets.
Shares of Verastem Oncology (VSTM) jumped 20% on Thursday, clocking its best day since Nov. 2025, as analysts lifted price targets following a positive update on the company’s experimental drug VS-7375 in second-line metastatic pancreatic ductal adenocarcinoma.On Wednesday, Verastem said that in it…